ArticleJournal of controlled release : official journal of the Controlled Release Society2016
Retracted: Self-assembled Phenylalanine-α,β-dehydrophenylalanine Nanotubes for Sustained Intravitreal Delivery of a Multi-targeted Tyrosine Kinase Inhibitor.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Retraction of
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). This article has been retracted at the request of the Investigation Committee of the University of Colorado, Denver, USA, and the Editor. The Committee has come to the conclusion that author Kadam has knowingly and intentionally falsified and/or fabricated results by manipulating LC-MS/MS peak area data to smooth kinetics and/or alter statistical significance for Figure 6. The standard curve for the drug pazopanib was falsified to make it appear linear. In fact, the raw data for the standard curves were highly scattered and non-linear, resulting in an unusable standard curve. As a result, the pazopanib values calculated from the fabricated curve are completely unreliable. The Committee found no evidence that any of the other authors was aware of and/or participated in any activity amounting to Scientific Misconduct.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.